Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials

详细信息    查看全文

• 作者：Marko Stojanović ; Milica Prostran…
• 关键词：Thiazolidinediones ; Pioglitazone ; Rosiglitazone ; Endothelial dysfunction ; Flow ; mediated dilation
• 刊名：European Journal of Clinical Pharmacology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：72
• 期：4
• 页码：385-398
• 全文大小：1,872 KB
• 参考文献：1.Radenković M (2014) Pioglitazone and endothelial dysfunction: pleiotropic effects and possible therapeutic implications. Sci Pharm 82:709–721CrossRef PubMed PubMedCentral
  2.Diamant M, Heine RJ (2003) Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 63:1373–1405CrossRef PubMed
  3.Radenković M, Stojanović M, Potpara T, Prostran M (2013) Therapeutic approach in the improvement of endothelial dysfunction: the current state of the art. Biomed Res Int 2013:252158PubMed PubMedCentral
  4.Stojanović M, Radenković M (2015) Vitamin D versus placebo in improvement of endothelial dysfunction: a meta-analysis of randomized clinical trials. Cardiovasc Ther 33:145–154CrossRef PubMed
  5.Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, et al. (2015) The role of vascular biomarkers for primary and secondary prevention. Atherosclerosis 241:507–532CrossRef PubMed
  6.Rizza S, Cardellini M, Porzio O, Pecchioli C, Savo A, Cardolini I, et al. (2011) Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. Atherosclerosis 215:180–183CrossRef PubMed
  7.Tsuchiya K, Akaza I, Yoshimoto T, Hirata Y (2009) Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes. Endocr J 56:691–698CrossRef PubMed
  8.Asnani S, Kunhiraman B, Jawa A, Akers D, Lumpkin D, Fonseca V (2006) Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Metab Syndr Relat Disord 4:179–184CrossRef PubMed
  9.Hong SJ, Choi SC, Cho JY, Joo HJ, Park JH, Yu CW, et al. (2015) Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis. Circ J 79:880–888CrossRef PubMed
  10.Rudofsky Jr G, Reismann P, Grafe IA, Konrade I, Djuric Z, Tafel J, et al. (2007) Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity. Horm Metab Res 39:665–671CrossRef PubMed
  11.Naka KK, Kalantaridou SN, Kravariti M, Bechlioulis A, Kazakos N, Calis KA (2011a) Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 95:203–209CrossRef PubMed
  12.Lee JW, Hong SJ, Jeong HS, Joo HJ, Park JH, Ahn CM, et al. (2013) Effects of a PPAR-γ (peroxisome proliferator-activated receptor-gamma) activator on flow-mediated brachial artery dilation and circulating level of microRNA-21 in hypertensive type 2 diabetic patients. J Korean Soc Hypertens 19:99–111CrossRef
  13.Naka KK, Papathanassiou K, Bechlioulis A, Pappas K, Kazakos N, Kanioglou C (2011b) Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin. Diab Vasc Dis Res 8:195–201CrossRef PubMed
  14.Walcher T, Walcher D, Hetzel J, Mielke C, Rau M, Rittig K, et al. (2010) Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study. Diab Vasc Dis Res 7:178–185CrossRef PubMed
  15.Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF, Lee YT (2006) Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 98:1057–1062CrossRef PubMed
  16.Esposito K, Ciotola M, Carleo D, Schisano B, Saccomanno F, Sasso FC, et al. (2006) Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29:1071–1076CrossRef PubMed
  17.Desch S, Sonnabend M, Niebauer J, Sixt S, Sareban M, Eitel I, et al. (2010) Effects of physical exercise versus rosiglitazone on endothelial function in coronary artery disease patients with prediabetes. Diabetes Obes Metab 12:825–828CrossRef PubMed
  18.Sidhu JS, Cowan D, Kaski JC (2004) Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 94:151–156CrossRef PubMed
  19.Chan DT, Watts GF, Irish AB, Dogra GK (2011) Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. Nephrol Dial Transplant 26:3543–3549CrossRef PubMed
  20.Sixt S, Rastan A, Desch S, Sonnabend M, Schmidt A, Schuler G, et al. (2008) Exercise training but not rosiglitazone improves endothelial function in prediabetic patients with coronary disease. Eur J Cardiovasc Prev Rehabil 15:473–478CrossRef PubMed
  21.Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O’Connor C, et al. (2003) The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 52:173–180CrossRef PubMed
  22.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100CrossRef PubMed PubMedCentral
  23.Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.3.0. The Cochrane Collaboration. www.​cochranehandbook​.​org
  24.Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRef PubMed
  25.Sahebkar A (2014) Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials. Vasc Med 19:54–66CrossRef PubMed
  26.Lunder M, Janić M, Jug B, Sabovič M (2012) The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial. Eur J Intern Med 23:261–266CrossRef PubMed
  27.Takagi H, Umemoto T (2014) A meta-analysis of randomized controlled trials of telmisartan for flow-mediated dilatation. Hypertens Res 37:845–851CrossRef PubMed
  28.Li S, Wu Y, Yu G, Xia Q, Xu Y (2014) Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials. PLoS One 9:e90217CrossRef PubMed PubMedCentral
  29.Zhang L, Gong D, Li S, Zhou X (2012) Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis 223:78–85CrossRef PubMed
  30.Shahin Y, Khan JA, Samuel N, Chetter I (2011) Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 216:7–16CrossRef PubMed
  31.Wang Q, Liang X, Wang L, Lu X, Huang J, Cao J, et al. (2012) Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis 221:536–543CrossRef PubMed
  32.Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, et al. (2008) Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 88:38–50PubMed
  33.Ashor AW, Lara J, Siervo M, Celis-Morales C, Oggioni C, Jakovljevic DG, et al. (2015) Exercise modalities and endothelial function: a systematic review and dose-response meta-analysis of randomized controlled trials. Sports Med 45:279–296CrossRef PubMed
  34.Li SH, Tian HB, Zhao HJ, Chen LH, Cui LQ (2013) The acute effects of grape polyphenols supplementation on endothelial function in adults: meta-analyses of controlled trials. PLoS One 8:e69818CrossRef PubMed PubMedCentral
  35.Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P (2005) Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54:2206–2211CrossRef PubMed
  36.Albertini JP, McMorn SO, Chen H, Mather RA, Valensi P (2007) Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. Atherosclerosis 195:e159–e166CrossRef PubMed
  37.Perampaladas K, Gori T, Parker JD (2012) Rosiglitazone causes endothelial dysfunction in humans. J Cardiovasc Pharmacol Ther 17:260–265CrossRef PubMed
  38.Takase H, Nakazawa A, Yamashita S, Toriyama T, Sato K, Ueda R, et al. (2007) Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers. Metabolism 56:559–564CrossRef PubMed
  39.Tahara N, Yamagishi S, Mizoguchi M, Tahara A, Imaizumi T (2013) Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. Rejuvenation Res 16:344–351CrossRef PubMed
  40.King DE, Player M, Everett CJ (2012) The impact of pioglitazone on ADMA and oxidative stress markers in patients with type 2 diabetes. Prim Care Diabetes 6:157–161CrossRef PubMed
  41.Matsumoto T, Noguchi E, Kobayashi T, Kamata K (2007) Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free RadicBiol Med 42:993–1007CrossRef
  42.Hernanz R, Martín Á, Pérez-Girón JV, Palacios R, Briones AM, Miguel M, et al. (2012) Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function. Br J Pharmacol 166:1303–1319CrossRef PubMed PubMedCentral
  43.Lu X, Guo X, Karathanasis SK, Zimmerman KM, Onyia JE, Peterson RG, et al. (2010) Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats. Cardiovasc Diabetol 9:19CrossRef PubMed PubMedCentral
  44.Kaur T, Goel RK, Balakumar P (2010) Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction. Arch Pharm Res 33:611–618CrossRef PubMed
  45.Khazaei M, Salehi E (2012) Rosiglitazone enhances neovascularization in diabetic rat ischemic hindlimb model. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 156:312–317CrossRef PubMed
  46.Sigmund CD (2010) Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency. Hypertension 55:437–444CrossRef PubMed PubMedCentral
  47.Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. (2008) Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 3:845–851CrossRef
  48.Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, et al. (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349–3354CrossRef PubMed PubMedCentral
  49.Woodcock J, Sharfstein JM, Hamburg M (2014) Regulatory action on rosiglitazone by the U.S. Food and drug administration. N Engl J Med 363:1489–1491CrossRef
  50.Wang T, Ning G, Bloomgarden Z (2013) Diabetes and cancer relationships. J Diabetes 5:378–390CrossRef PubMed
  
• 作者单位：Marko Stojanović (1)
  Milica Prostran (1)
  Miroslav Radenković (1)
  
  1. Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, PO Box 38, Belgrade, 11129, Serbia
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Pharmacology and Toxicology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1041

文摘

Aims Thiazolidinediones administration is assumed to be related with an improvement of endothelial dysfunction (ED); nevertheless, previous studies have been inconsistent. For this reason, the present meta-analysis was directed to estimate if thiazolidinediones were related to endothelial dysfunction improvement by using flow-mediated dilation (FMD) measurement.